Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to gram-positive bacteria

Infectious Diseases in Clinical Practice

Volumn 12, Issue 6, 2004, Pages 322-327

  Naber, Kurt G ^a   Eisenstein, Barry I ^b,c   Tally, Francis P ^c  

^a Urologische Klinik   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DAPTOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIURIA; BLADDER DIVERTICULUM; BLADDER RECONSTRUCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENTEROCOCCUS FAECALIS; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL DISEASE; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; NEUROGENIC BLADDER; PYURIA; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION; URINARY TRACT SURGERY; UROLITHIASIS;

EID: 4544365525     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000144898.12957.eb     Document Type: Article

References (22)

1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003;49(2):53-70.
2. Melekos M, Naber K. Complicated urinary tract infections. Int J Antimicrob Agents. 2000;15(4):247-256.
3. Preheim L. Complicated urinary tract infections. Am J Med. 1985; 79(2A):62-66.
4. Kremery S, Naber K. Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group. Int J Antimicrob Agents. 1999;11:133-138.
5. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon. 2003;49(2):71-82.
6. Wagenlehner F, Naber K. Bacterial urinary tract infections - What is only an annoyance, when is risk involved? Ther Umsch. 2002;59(9): 464-468.
7. Rubenstein J, Schaeffer A. Managing complicated urinary tract infections: the urologic view. Infect Dis Clin North Am. 2003;17(2): 333-351.
8. Biering-Sorensen F, Bagi P, Hoiby N. Urinary tract infections in patients with spinal cord lesions: treatment and prevention. Drugs. 2001; 61(9):1275-1287.
9. McCue JD. The management of complicated urinary tract infections. Available at: http://www.dpa.com.hk/pdf/info/info_alart_01.pdf Accessed January 8, 2004.
10. Wagenlehner FMA, Niemetz A, Dalhoff A, et al. Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infection: 1994-2000. Int J Antimicrob Agents. 2002;19:557-564.
11. Bouza E, San Juan R, Munoz P, et al. A European perspective on nosocomial urinary tract infections: report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 Study). Clin Microbiol Infect. 2001;7:523-531.
12. Schaeffer A. The expanding role of fluoroquinolones. Am J Med. July 8, 2002;113(suppl 1):45S-54S.
13. Ishihara S, Yamada T, Yokoi S, et al. Antimicrobial activity of imipenem against isolates from complicated urinary tract infections. Int J Antimicrob Agents. 2002;19(6):565-569.
14. Roberts J. Management of pyelonephritis and upper urinary tract infections. Urol Clin North Am. 1999;26(4):753-763.
15. Naber K. Therapy of complicated urinary tract infections. Wien Med Wochenschr. 1991;141(23-24):552-555.
16. Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Expert Opin Investig Drugs. 2003;12(2):117-137.
17. Cidecin (daptomycin for injection) Investigator's Brochure. Edition 4.1: Cubist Pharmaceuticals, Inc; February 11, 2003.
18. Naber K, Wagenlehner F, Lehn N. In vitro activity of daptomycin versus linezolid, vancomycin, and ampicillin (enterococci) against Gram-positive uropathogens causing complicated urinary tract infections. Poster SA 107. Paper presented at: 23rd International Congress of Chemotherapy; 7-9 June, 2003; Durban, South Africa.
19. CUBICIN Product Information. Lexington, Mass: Cubist Pharmaceuticals 2003.
20. Silverman JA, Oliver N, Andrew T, et al. Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001;45(6):1799-1802.
21. Physician's Desk Reference. 57th ed. Montvale: Thomson Healthcare; 2003.
22. Gonzalez MA, Moranchel AH, Duran S, et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother. 1985;28(2):235-239.